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Abstract
Background: Deposits of aggregated amyloid-β protein (Aβ) are a pathological hallmark of Alzheimer’s disease
(AD). Thus, one therapeutic strategy is to eliminate these deposits by halting Aβ aggregation. While a variety of
possible aggregation inhibitors have been explored, only nanoparticles (NPs) exhibit promise at low
substoichiometric ratios. With tunable size, shape, and surface properties, NPs present an ideal platform for
rationally designed Aβ aggregation inhibitors. In this study, we characterized the inhibitory capabilities of gold
nanospheres exhibiting different surface coatings and diameters.
Results: Both NP diameter and surface chemistry were found to modulate the extent of aggregation, while NP
electric charge influenced aggregate morphology. Notably, 8 nm and 18 nm poly(acrylic acid)-coated NPs
abrogated Aβ aggregation at a substoichiometric ratio of 1:2,000,000. Theoretical calculations suggest that this
low stoichiometry could arise from altered solution conditions near the NP surface. Specifically, local solution pH
and charge density are congruent with conditions that influence aggregation.
Conclusions: These findings demonstrate the potential of surface-coated gold nanospheres to serve as tunable
therapeutic agents for the inhibition of Aβ aggregation. Insights gained into the physiochemical properties of
effective NP inhibitors will inform future rational design of effective NP-based therapeutics for AD.
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Background
In 1901, Alois Alzheimer examined a patient experiencing
multiple neurological symptoms, including pronounced
memory loss [1], marking the first diagnosis of what is
now the most common neurodegenerative disorder,
Alzheimer’s disease (AD). Amyloid plaques, comprised of
aggregated amyloid-β (Aβ) protein [2] and found through-
out the cerebral cortex [1], are a pathological hallmark of
AD. While monomeric Aβ is inert [3], Aβ aggregates
induce neurotoxicity [4], inhibit neuronal long-term
potentiation [5–7], induce synapse loss [8], and disrupt
memory and complex learned behavior [9]. As a result,
halting Aβ aggregation is one promising therapeutic
strategy for AD. However, extensive investigation of small
molecules and peptides as inhibitors of Aβ aggregation
has failed to yield a successful therapeutic, necessitating
the exploration of novel therapeutic agents.
Nanoparticles (NPs) have emerged as attractive thera-
peutic and diagnostic tools with applications in medical
imaging, analytics, and drug delivery [10–14]. NPs can
be synthesized from a wide range of materials including
metals, polymers, and carbon-based molecules [11–14].
Furthermore, the ease with which NP size, shape, and
surface properties are controlled [10–14] render NPs an
ideal tunable platform for therapeutic applications.
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Among the growing body of potential therapeutic ap-
plications for NPs is their ability to modulate amyloid
protein aggregation [15–19]. Inhibition of Aβ aggrega-
tion, specifically, has been reported for NPs ranging in
size from <10 nm to several hundred nanometers and
exhibiting diverse surface chemistries [20–28]. More-
over, these effects have been observed at picomolar NP
concentrations and substoichiometric ratios of NP to
protein. While a wide array of small molecules and pep-
tides can disrupt Aβ aggregation [29, 30], none have been
as effective as NPs at substoichiometric ratios, thus
increasing their potential for delivery of therapeutically
effective concentrations to the brain. However, variations
in NP size and surface chemistry can result in the con-
trasting promotion of Aβ aggregation [21, 23, 24, 31–33].
Thus, there exists a need to better understand the impact
of NP physiochemical properties upon Aβ aggregation.
Using spherical NPs that vary in surface coating and
size, this study investigates the effect that NP surface
chemistry, charge, and diameter have upon Aβ aggrega-
tion. Gold was selected as the NP core material because
gold NPs are readily synthesized, easily functionalized,
and highly stable against oxidative dissolution [34–36].
Examination of four NP surface chemistries as well as
three different NP diameters revealed that electric
charge, surface chemistry, and size all modulate the abil-
ity of gold nanospheres to inhibit Aβ aggregation. While
NP diameter and surface chemistry impact the extent of
inhibition, electric charge determines the ability to influ-
ence aggregate morphology. In particular, smaller, anionic
NPs are superior inhibitors, halting aggregation at substoi-
chiometric ratios as low as 1:2,000,000 with the protein.
Theoretical calculations suggest that such low stoichiom-
etry may be achieved through NP-induced alterations to
local solution conditions, including pH and charge dens-
ity. Together, these findings identify surface-coated gold
NPs as potential therapeutic agents for AD and provide
insight into the physiochemical properties displayed by
NPs that effectively inhibit Aβ aggregation.
Results and discussion
As part of the emergence of NPs in medical applications,
development of NPs as inhibitors of amyloid protein
aggregation has garnered attention [15–19]. With the
ability to vary NP physiochemical properties, including
material, size, and charge, NPs offer a tunable platform
to modulate amyloid protein aggregation [37, 38]. How-
ever, the influence of NP characteristics on protein
aggregation is poorly understood [15–17]. This study
characterizes the inhibition of Aβ aggregation by gold
nanospheres with varying surface chemistry and diameter.
A cellular assay was used to probe the neurotoxicity of
synthesized NPs, while a fluorescent amyloid-binding
dye and transmission electron microscopy (TEM) were
employed to characterize NP-induced alterations in Aβ
aggregate formation and morphology, respectively.
These investigations define a role for NP size, electric
charge, and surface chemistry in determining inhibitory
capabilities, and a theoretical model provides insight
into the possible mechanism of inhibition.
Toxicity of surface-coated gold NPs
Toxicity of gold NPs is dependent upon their size, shape,
and surface coating [39–43]. To probe the biocompati-
bility of synthesized NPs as therapeutic agents, their
potential to elicit a toxic response was evaluated within
human neuroblastoma SH-SY5Y cells, a widely used
model for the study of prospective AD therapeutics.
Following 24 h exposure of SH-SY5Y cells to surface-
coated NPs, cellular metabolic activity was assessed using
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-
5-carboxanilide (XTT) reduction. At NP concentrations of
100 pM and 200 pM, cellular viability remained >95%
following incubation with 18 nm NPs displaying citrate,
poly(acrylic acid) (PAA), or polyelectrolytes poly(allylami-
ne)hydrochloride (PAH) surface chemistries (Fig. 1a). In
contrast, 18 nm cetyltrimethylammonium bromide
(CTAB) coated NPs reduced cellular viability to less than
20%, a viability level comparable to cells treated with 2%
Triton-X, thus indicating their propensity to induce tox-
icity. This result is congruent with observations that
CTAB-coated nanoparticles are toxic toward other cell
types [39–41], while their further overcoating reduces the
toxic effects [39, 41]. When cells were incubated in the
presence of PAA-coated NPs of varying size, NPs 8 nm
and 18 nm in diameter did not elicit toxicity. In contrast,
40 nm PAA-coated NPs were toxic, with both 100 pM
and 200 pM NPs reducing cellular viability to less than
10% (Fig. 1b). Similarly, other studies have shown size-
dependent toxicity for nanoparticles, with larger sizes
eliciting a more toxic response [42, 43]. Results here
demonstrate that NP toxicity toward SH-SY5Y cells is
influenced by both surface chemistry and size and that
several NPs considered in the current study are inert in
SH-SY5Y cultures.
Effect of surface-coated gold NPs on ThT fluorescence
detection of Aβ1–40 aggregates
The plasmonic nature of NPs imparts an ability to ab-
sorb and scatter light, which may enhance or quench
fluorescent signals [44]. This property presents the pos-
sibility that NPs could alter fluorescence of thioflavin T
(ThT), which binds the β-sheet structure characteristic
of fibrillar Aβ aggregates to yield a shifted, enhanced
fluorescence and is thus commonly used to monitor the
progression of aggregation. To ensure that observed dif-
ferences in ThT fluorescence accurately reflect changes in
Aβ aggregate formation, ThT fluorescence was assessed
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for 5 μM pre-formed fibrillar Aβ1–40 aggregates incubated
for 2 h in the absence (control) or presence of 5–200 pM
surface-coated NPs. These concentrations are representa-
tive of diluted solutions used for monitoring aggregation.
Among 18 nm NPs, ThT fluorescence detection of Aβ1-40
fibrils was unaltered by NPs displaying citrate, PAA, and
PAH surface chemistries (Fig. 2a). In contrast, CTAB-
coated NPs significantly quenched ThT fluorescence
detection of aggregated Aβ1-40 at concentrations of 50 pM
and higher. When PAA-coated NPs of varying diameter
were compared, neither 8 nm nor 18 nm NPs altered the
detection of Aβ1-40 fibrils by ThT; however, ThT fluores-
cence detection was again significantly quenched by the
presence of 40 nm PAA-coated NPs (Fig. 2b). Other stud-
ies have shown that small molecule inhibitors of Aβ
aggregation can also reduce ThT fluorescence detection of
Aβ aggregates, although via a different mechanism of
binding competition [45, 46]. These studies advocate cau-
tion toward the unmitigated use of ThT fluorescence to
study Aβ aggregation inhibitors. As a result, assessment of
the effect of 18 nm CTAB-coated NPs and 40 nm PAA-
coated NPs was limited to TEM analysis.
18 nm surface-coated gold NPs inhibit Aβ1–40 monomer
aggregation and alter fibril morphology
The effect of synthesized NPs on Aβ aggregation was
evaluated using Aβ1–40, the most abundant monomeric
isoform in vivo [47] as well as the dominant species
found in amyloid plaques [48]. Aggregation of 40 μM
monomeric protein was stimulated by continuous agita-
tion, and ThT fluorescence was used to monitor the
formation of β-sheet amyloid aggregates. Aβ1–40









































Fig. 1 Toxicity of surface-coated gold NPs. SH-SY5Y human
neuroblastoma cells were incubated (24 h) alone (negative control)
or in the presence of 100 pM (closed bars) or 200 pM (open bars)
NPs. a Treatment with 18 nm NPs coated with citrate, CTAB, PAA,
or PAH. b Treatment with 8 nm, 18 nm, or 40 nm NPs coated with
PAA. Treatment with 2% Triton-X (Tr-X) served as a positive control.
Cellular viability was assessed using XTT reduction. Results are
shown as the percentage of viable cells relative to the negative
control and represent the mean of 2–3 independent experiments,




























































Fig. 2 Effect of surface-coated gold NPs on ThT fluorescence detection
of Aβ1-40 aggregates. Aβ1–40 fibrils diluted in 40 mM Tris–HCl (pH 8.0) to
a final concentration of 5 μM were combined with 8.75 μM ThT and in-
cubated (2 h) alone (control) or with 5 pM, 10 pM, 20 pM, 50 pM, 100
pM, or 200 pM NPs. a Incubation with 18 nm NPs displaying citrate (■),
CTAB (●), PAA (▲), or PAH (♦) surface chemistries. b Incubation with
8 nm (▶), 18 nm (▲), or 40 nm (◀) NPs coated with PAA. ThT fluores-
cence was evaluated, and results are expressed as the fraction of ThT
fluorescence observed for the control. Error bars represent SEM,
n = 3. †p < 0.05 and *p < 0.001 vs. control
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aggregation yielded a characteristic growth pattern dis-
playing an initial lag phase, indicative of nucleation, which
was followed by rapid aggregate growth that ceased at
equilibrium, as evidenced by plateau of the fluorescence
signal (Fig. 3a). Inhibition of Aβ1–40 aggregation by NPs
was quantified via changes in the lag time and equilibrium
plateau. Extension of the lag time occurs early in aggrega-
tion and is indicative of an increased time to nucleation.
Lag extension was calculated as a fold-change, relative to
the control, in the time at which ThT fluorescence first in-
creases. Reduction of the plateau fluorescence is evidenced
at equilibrium and indicates a decrease in the total quan-
tity of aggregates containing β-sheet structure. Plateau
reduction was calculated as the percentage decrease in
ThT fluorescence at equilibrium.
When monomer aggregation was stimulated in the pres-
ence of NPs, none of the NPs were capable of delaying
nucleation to extend the lag time. However, at 200 pM
several NPs did decrease the quantity of β-sheet aggre-
gates formed at equilibrium (Fig. 3a). Aggregates formed
in the presence of 200 pM citrate- or PAH-coated NPs
exhibited a 19 ± 8% and 59 ± 9% reduction of the equilib-
rium plateau, respectively (Table 1). The most pronounced
effect was observed with PAA-coated NPs, which com-
pletely abrogated aggregation. Inhibition of Aβ1–40 aggre-
gation by surface-coated NPs was also observed to be
dose dependent (Table 1). Inhibition by PAH-coated NPs
decreased from nearly 60% at a concentration of 200 pM
to less than 45% at a concentration of 20 pM (Fig. 3b,
Table 1), and citrate-coated NPs were ineffective at con-
centrations below 200 pM (Table 1). PAA-coated NPs,
however, continued to fully abrogate inhibition at concen-
trations as low as 20 pM, or a 1:2,000,000 substoichio-
metric ratio of NPs to Aβ1-40 (Table 1). To ensure these
inhibitory effects were characteristic of the NPs and not
just surface coatings, monomer aggregation was also
performed in the presence of 100 μM solubilized sodium
citrate, CTAB, PAA, or PAH; each failed to elicit any
inhibitory effect (results not shown).
To confirm inhibition of Aβ1–40 aggregation by syn-
thesized NPs as well as to further investigate changes
in aggregate morphology, TEM images were acquired
following a time point after which aggregation reac-
tions had reached equilibrium. Aggregates formed in
the absence of NPs exhibit a network of filamentous
fibrils comprised of single or multiple strands (Fig. 4a, d).
This morphology is in agreement with other studies of Aβ
aggregation [20, 24, 27, 33].
When Aβ1-40 aggregates were formed in the presence of
200 pM citrate-coated (Fig. 4b) or PAH-coated (Fig. 4c)
NPs, the quantity of aggregates was reduced compared to
the control. These results corroborate the plateau reduc-
tions observed via ThT fluorescence. TEM additionally
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Fig. 3 Effect of 18 nm surface-coated gold NPs on Aβ1–40 monomer
aggregation. Aβ1–40 monomer diluted to 40 μM in 40 mM Tris–HCl
(pH 8.0) was aggregated alone (control, Ο) or in the presence of
surface-coated NPs. a Aggregation in the presence of 200 pM NPs
displaying citrate (■), PAA (▲), or PAH (♦) surface chemistries.
b Aggregation in the presence of 200 pM (♦), 100 pM ( ), or
20 pM ( ) PAH-coated NPs. Monomer aggregation was induced by
continuous agitation and monitored periodically via ThT fluorescence.
ThT fluorescence, expressed as the fraction of the control equilibrium
plateau, is plotted versus relative time, which is the fraction of the
control lag time. Results are representative of 3–5 independent
experiments
Table 1 Percent inhibition of Aβ1–40 monomer aggregation
observed in the presence of surface-coated NPsa,b
NP type [NP]
Surface Modification Diameter 20 pM 100 pM 200 pM
Citrate 18 nm 4.3 ± 2.6 0.0 ± 0.0 19 ± 8*
PAH 18 nm 45 ± 4* 47 ± 5* 59 ± 9*
PAA 18 nm 97 ± 2* 99 ± 0* 95 ± 3*
PAA 8 nm 95 ± 3* 92 ± 4* 94 ± 1*
*p < 0.001 compared to control
aInhibition is expressed as plateau reduction, or the percentage of reduction in
the equilibrium plateau compared to the control
bParameters are expressed as mean ± SEM, n = 3–5
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NPs on Aβ1–40 aggregation, for which analysis by ThT
fluorescence was precluded. Aggregates formed in the
presence of 200 pM CTAB-coated NPs exhibited a re-
duction in aggregate quantity (Fig. 4e), demonstrating
that these NPs can also inhibit Aβ1–40 aggregation.
When Aβ1–40 aggregation was stimulated in the pres-
ence of 200 pM 18 nm PAA-coated NPs, an absence of
filamentous aggregates was observed (Fig. 4g), substan-
tiating the ability of these NPs to abrogate aggregation.
Together, TEM results confirm the relative inhibitory
capabilities of surface-coated NPs observed by ThT fluor-
escence as well as the complete inhibition imparted by
PAA-coated NPs.
While the most effective inhibitors were NPs coated
with anionic PAA, NPs exhibiting both negative and
positive surface charges inhibited Aβ aggregation. This
observation agrees with previous studies that have
described both anionic and cationic NPs as inhibitors of
protein aggregation [20, 21, 23–25, 28, 49–55]. Among
the NPs examined within the current study, however,
those with anionic citrate and PAA coatings were more
effective inhibitors than those with cationic CTAB and
PAH coatings. This finding aligns with other studies that
have observed superior inhibitory capabilities by anionic
NPs over cationic NPs [20, 21, 23, 25, 28]. Among an-
ionic NPs, PAA-coated particles exhibited superior in-
hibitory capabilities over citrate-coated particles. Other
studies also report variances in inhibition of amyloid
protein aggregation by NPs displaying different surface
chemistries with the same electric charge [22, 25]. In
comparison to monomeric citrate, polymeric PAA will
exhibit molecular reorganization transitions with the
local solution environment [56]. These transitions can
result in spatially dependent changes to physical parame-
ters that may facilitate inhibition, as discussed in the
next section.
TEM images further revealed that NPs with different
coatings exert different effects on aggregate morphology.
While aggregates formed in the presence of anionic
citrate-coated NPs exhibited a morphology similar to the
control (Fig. 4b), aggregates formed in the presence of
cationic NPs demonstrated altered morphologies. PAH-
coated NPs induced the formation of an increased num-
ber of thin, elongated aggregate structures (Fig. 4c),
while CTAB-coated NPs induced the formation of short,
thick associated aggregates (Fig. 4e). Thus, these results
demonstrate the ability of cationic, but not anionic, NPs
to influence aggregate morphology. Other studies have
described similar NP-induced changes in aggregate
structure, with a diverse array of morphologies reported
[20, 21, 26, 49, 50, 52, 54, 55]. However, these observa-
tions are not confined to cationic NPs.
NP size influences inhibition of Aβ1–40 monomer
aggregation by PAA-coated gold NPs
The complete inhibition of Aβ1–40 aggregation ob-
served in the presence of 18 nm PAA-coated NPs
prompted further experimentation to elucidate the ef-
fect of PAA-coated NP size on inhibitory capabilities.
PAA-coated NPs exhibiting diameters of 8 nm, 18 nm,
and 40 nm were examined for their ability to attenuate









Fig. 4 Effect of surface-coated gold NPs with different surface coatings and diameters on Aβ1-40 aggregate morphology. Aβ1–40 monomer diluted
to 40 μM in 40 mM Tris–HCl (pH 8.0) was aggregated alone (control, panels a, d) or in the presence of 200 pM citrate-coated (panel b), PAH-coated
(panel c), CTAB-coated (panel e), or PAA-coated (panel g) NPs 18 nm in diameter. Additionally, monomer was aggregated in the presence of 200 pM
PAA-coated NPs exhibiting diameters of 8 nm (panel f) or 40 nm (panel h). Monomer aggregation was induced by continuous agitation, and the control
reaction was monitored periodically via ThT fluorescence. Upon evidence of equilibrium, samples were gridded and visualized by TEM. Results are
representative of 2 independent experiments. Images are shown relative to a scale bar of 500 nm at 100,000x (panels a-c, e-g) or 75,000x
(panels d, h) magnification
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span the range of sizes able to cross the blood–brain
barrier and undergo clearance from the body [57, 58].
Similar to the inhibition observed in the presence of
18 nm PAA-coated NPs, the smaller 8 nm NPs reduced
the equilibrium plateau by >90% at concentrations as
low as 20 pM (Fig. 5, Table 1), demonstrating their
effectiveness as Aβ aggregation inhibitors. This result
was corroborated by the absence of aggregate material
observed via TEM (Fig. 4f ). In contrast, 40 nm PAA-
coated NPs were ineffective at preventing the formation
of Aβ1-40 aggregates. Although these NPs quenched
ThT fluorescence (Fig. 2), precluding their assessment
via ThT, their inability to prevent aggregate formation
was evidenced by TEM images displaying a similar
quantity of aggregate material (Fig. 4h) compared to
the control of equivalent magnification (Fig. 4d). These
results demonstrate that only smaller PAA-coated NPs
are capable of serving as effective inhibitors of Aβ1–40
aggregation. This observation is in agreement with
other studies reporting variations in inhibition of amyl-
oid protein aggregation by NPs exhibiting different
sizes [21, 28]. As in the current study, larger NPs are
consistently less effective inhibitors, suggesting that
high NP curvature may be needed to impart inhibitory
capabilities.
Both 8 nm and 18 nm PAA-coated nanospheres were
capable of abrogating Aβ aggregation at a substoichio-
metric ratio of 1:2,000,000. While other studies have pro-
posed NP-protein binding as the mode of aggregation
inhibition, this extremely low NP to monomer ratio sug-
gests that these surface-coated NPs are acting via another
mechanism. Moreover, TEM images show that NPs did
not co-localize with aggregates and that morphological
changes were not isolated to regions near NPs. A similar
lack of interaction with aggregated protein is also reported
for other NP types [20, 50, 54, 59]. These observations
suggest a dynamic interaction between NP-localized pro-
tein and the bulk solution.
Theoretical calculations indicate that surface charged NPs
alter local solution conditions that can influence Aβ
aggregation
The strikingly low stoichiometry at which inhibition of
Aβ1–40 aggregation by PAA-coated NPs was observed
as well as the lack of association between NPs and Aβ
aggregates within TEM images suggest that interactions
other than sequestration of Aβ1–40 monomer at the NP
surface may play a role in the inhibitory capabilities of
surface-coated NPs. A potential mechanism that can
account for these congruent observations exists in the
effect that the curved, charged NP surface has upon
local solution conditions, including pH and ionic
strength [21], both of which significantly influence Aβ ag-
gregation [60–62]. Specifically, Aβ aggregation is attenu-
ated in the presence of acidic and basic pH [61, 63–65],
while aggregation is promoted by the presence of a higher
ionic strength, or charge density [62, 66–70]. Moreover,
both solution pH [60, 65, 66, 71] and ionic strength [66,
67, 70] can modulate aggregate morphology. To explore
this possibility, a self-consistent molecular field theory
(SCMFT) was developed and implemented to describe
molecular organization near the curved, charged NP sur-
face. Theoretical calculation of the equilibrium concentra-
tions of solution species allowed for the determination of
local solution pH and charge density.
Theoretical calculations demonstrate pronounced
changes in solution pH and solution charge density
near the surface of 18 nm NPs suspended in 40 mM
Tris–HCl (pH 8.0) (Fig. 6). Cationic NP surfaces induce
an elevated local solution pH and a negative charge
density, while anionic NP surfaces depress the local so-
lution pH and induce a positive solution charge density.
These changes result from the system localizing coun-
terions near the NP surface to balance the NP surface
charge. The magnitude of NP-induced alterations is
consistent with conditions under which altered Aβ ag-
gregation would occur [37, 61, 62]. Moreover, a greater
absolute magnitude of surface charge produces more
pronounced changes in the local solution molecular
organization, leading to larger deviations from the bulk
solution. This observation is congruent with prior ex-
perimental reports in which NPs with a higher absolute
magnitude of surface charge imparted greater inhib-
ition [22, 25]. For NPs with a large magnitude of sur-
face charge, these effects extend several nanometers
beyond the NP surface. This spatial pervasiveness
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Fig. 5 Effect of 8 nm PAA-coated gold NPs on Aβ1–40 monomer
aggregation. Aβ1-40 monomer diluted to 40 μM in 40 mM Tris–HCl
(pH 8.0) was aggregated alone (control, Ο) or in the presence of 8 nm
PAA-coated NPs at concentrations of 200 pM (▶), 100 pM ( ), or
20 pM ( ). Monomer aggregation was induced by continuous agitation
and monitored periodically via ThT fluorescence. ThT fluorescence and
time values are presented as in Fig. 3. Results are representative of 3
independent experiments
Moore et al. Journal of Biological Engineering  (2017) 11:5 Page 6 of 11
would allow protein to exchange between local and
bulk solution conditions. Such exchange may impede
the formation of organized amyloid structures or disrupt
those structures formed within the bulk solution. Pre-
vious observations support such a dynamic exchange
[25, 59, 72] along with the dominance of nanoscale
surface properties over the bulk solution [16], which
may be partly due to the persistence of protein struc-
tures formed near the NP surface [72].
Interestingly, an asymmetry exists about the bulk solu-
tion values, with cationic NPs eliciting a more pronounced
change in charge density. This asymmetry is a manifest-
ation of differences between counterions that become lo-
calized to balance the NP surface charge. The cationic NP
surface draws hydroxide and chloride to its surface, with
chloride being the predominant species, while the anionic
NP surface draws hydronium and Tris to its surface, with
Tris predominating. In the latter case, because Tris is in
chemical equilibrium with its local environment through
the acid dissociation reaction (tr+⇄ tr +H+), the fraction
of Tris that is charged, and hence capable of balancing the
anionic NP surface charge, is interdependent upon the
local pH environment, thus causing a distinct effect upon
molecular organization. This asymmetric magnitude in
charge density combined with the opposing changes in
both local solution pH and charge density induced by
anionic vs. cationic NPs may contribute to the distinct
inhibitory effects observed for anionic and cationic NPs,
including the stronger inhibitory capabilities of anionic
NPs and the ability of cationic, but not anionic, NPs to
alter aggregate morphology. Moreover, polymeric PAA
can produce steric hindrance that results in a preference
for localizing protons over bulky ions, such as Tris. The
result is a more pronounced effect on the local pH com-
pared to citrate, congruent with the enhanced effective-
ness of PAA-coated vs. citrate-coated NPs.
Overall, theoretical results parallel experimental obser-
vations in both the current and prior studies, supporting
the hypothesis that inhibition of amyloid aggregation
may stem, in part, from NP-induced changes in local so-
lution conditions.
Conclusion
This study provides evidence that electric charge, sur-
face chemistry, and size can modulate the ability of
gold nanospheres to inhibit Aβ aggregation. NP surface
chemistry and size influence the extent of inhibition,
while electric charge defines NP ability to alter aggre-
gate morphology. Overall, PAA-coated NPs 18 nm and
smaller are superior inhibitors, abrogating aggregation
at substoichiometric ratios as low as 1:2,000,000 with
Aβ. Such low stoichiometric ratios coupled with the
lack of NP-aggregate association prompted investigation
for NP-induced changes in local solution conditions to
influence aggregation. A theoretical model describing
changes in local solution pH and charge density displays
congruencies with experimental observations to support
this potential mechanism. Cell viability assays further
demonstrated that the most effective NP inhibitors are
non-toxic. Together, these findings identify surface-coated
gold nanospheres as potential tunable therapeutic
agents for the inhibition of Aβ aggregation and provide




Aβ1–40 was purchased from AnaSpec, Inc. (San Jose, CA).
Gold (III) trichloride hydrate HAuCl4 · 3H2O, trisodium
citrate, sodium borohydride (NaBH4), ascorbic acid,


























Fig. 6 Effect of NP surface charge on local solution pH and charge
density. The equilibrium molecular organization near the surface of
NPs was modeled using a SCMFT incorporating water, hydronium,
hydroxide, chloride, and Tris. Theoretical calculations were performed
for 18 nm NPs in the presence of 40 mM Tris–HCl (pH 8.0) for NPs
exhibiting a positive (black lines) or negative (grey lines) surface charge
with absolute surface charge (σq) magnitudes of 4 e/nm2 (solid
lines), 1 e/nm2 (dashed lines), or 0.1 e/nm2 (dotted lines). Local
solution pH (panel a) and charge density (ρq) (panel b) are plotted
as a function of distance from the NP surface
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CTAB, ThT, Triton-X 100, XTT, and all cell culture
media and reagents were purchased from Sigma-Aldrich
(St. Louis, MO). The polyelectrolytes PAH and PAA were
also obtained from Sigma-Aldrich and used without fur-
ther purification. Sodium chloride (NaCl) was purchased
from Fisher Scientific. Uranyl acetate was purchased from
Electron Microscopy Sciences (Hatfield, PA).
Surface-coated gold NP synthesis and characterization
Surface-coated gold NPs of average core diameters
8 nm, 18 nm, and 40 nm were synthesized using a previ-
ously reported seeded growth method [73], described in
detail within Additional file 1. NPs in their citrate-
capped form were either used for experimentation,
coated with CTAB, which forms a bilayer on the surface
causing the trimethylammonuim headgroup to face the
aqueous solvent, or electrostatically over-coated in a
layer-by-layer fashion with PAA and PAH [74]. There-
fore, at pH 7, the nanomaterials would present either a
cationic (CTAB and PAH) or anionic (citrate and PAA)
surface. NPs were characterized using TEM and UV–vis
absorbance spectroscopy.
Toxicity of surface-coated gold NPs
Potential toxicity of surface-coated NPs was probed in
human neuroblastoma SH-SY5Y cells (American Type
Culture Collection, Manassus, VA). Cellular reduction of
XTT was employed to evaluate cellular metabolic activ-
ity following NP exposure. Cells, sustained and prepared
for experiments as described in Additional file 1, were
incubated (24 h) with NPs (100 pM or 200 pM) diluted
into medium, with medium alone (negative control), or
with 2% Triton-X 100 in medium (positive control).
Following incubation, cells were washed and treated
(24 h) with 0.33 mg/mL XTT and 8.3 μmol/L phenozene
methyl sulfate. Metabolically active cells reduce XTT to
an orange formazan product, for which absorbance
(450 nm) was measured using a BioTek Synergy 2 mi-
croplate reader (Winooski, VT). Results are reported as
a percentage of the negative control following back-
ground (medium containing XTT) subtraction.
Aβ1–40 monomer aggregation
Aβ1–40 monomer aggregation assays were performed simi-
lar to previously described methods [75]. Briefly, Aβ1–40
monomer, purified via size exclusion chromatography
(SEC) as described in Additional file 1, was diluted to
40 μM in 40 mM Tris–HCl (pH 8.0) and agitated (vortex,
800 rpm, 25 °C) alone (control) or with 20-200 pM NPs.
Periodically, a 20 μL aliquot was removed and combined
with 140 μL of 10 μM ThT, an amyloid-binding dye that
yields a shifted, enhanced florescence upon recognition of
the characteristic β-sheet structure of fibrillar Aβ aggre-
gates. Fluorescence (excitation = 450 nm, emission = 470-
500 nm) was evaluated using a Perkin-Elmer LS-45 lumi-
nescence spectrometer (Waltham, MA). Fluorescence
values were calculated as the integrated area under the
emission curve with baseline (ThT alone) subtraction and
plotted vs. aggregation time.
ThT detection of Aβ1–40 aggregates in the presence of
surface-coated gold NPs
To ensure that NPs do not compromise ThT detection,
ThT fluorescence was evaluated for 5 μM Aβ1–40 pre-
formed fibrils, prepared as described in Additional file 1,
in the presence of 8.75 μM ThT and 5-200 pM NPs (con-
centrations congruent with those of diluted samples used
to monitor aggregation). ThT fluorescence was measured
after 2 h incubation. Compromised ThT detection was
evaluated as a decrease in ThT fluorescence relative to
that observed for fibrils in the absence of NPs and
expressed as the fraction of ThT fluorescence observed for
the control.
Morphological evaluation of Aβ1–40 aggregates
To evaluate Aβ1–40 aggregate morphology, monomer ag-
gregation reactions were prepared for TEM following
the time point at which the control reaction reached
equilibrium (assessed via ThT). As described previously
[75], a 10 μL sample was placed on a 300 mesh formvar-
carbon supported copper grid (Electron Microscopy
Sciences, Hatfield, PA). After 3 min, the sample was
wicked away from the bottom side of the grid using filter
paper. Sample application was repeated twice, and grids
were allowed to air dry (24 h). Gridded samples were
stained (10 min) with 2% aqueous uranyl acetate, excess
stain was wicked away, and grids were allowed to dry
(24 h). Imaging was performed using a JEOL 200CX
TEM (Tokyo, Japan) with an accelerating voltage of
120 kV. Blinded observation of samples with random se-
lection of grid areas was implemented to reduce bias.
Statistical analysis
Using GraphPad Prism 5 software (San Diego, CA), the ef-
fect of NPs on aggregation was evaluated using a one-way
analysis of variance (ANOVA) with Dunnett’s post-test,
and the effect of NPs on ThT detection was evalu-
ated using a two-way ANOVA with Bonferroni post-
test. p < 0.05 was considered significant.
Thermodynamic model
A SCMFT was developed and parameterized to model the
equilibrium molecular organization near the interface of
surface-coated NPs suspended in 40 mM Tris–HCl
(pH 8.0). The NP surface was modeled as a sphere bearing
a fixed surface charge where spherical symmetry was im-
posed. Five mobile species (water, hydronium, hydroxide,
chloride, and Tris) were accounted for explicitly to
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capture the solvent environment. The chemical equilib-
rium of Tris is integrated into the model and made
dependent upon the local solvent environment. The con-
centration of chloride was parameterized to achieve elec-
troneutrality within the bulk solution. The SCMFT is
expressed mathematically as a dimensionless free energy
functional. The equilibrium molecular organization is de-
termined through the minimization of this functional.
Further details can be found in Additional file 1. This
model was used to predict the molecular organization
near the NP surface, from which the pH and charge dens-
ity were determined a function of distance from the NP
surface. Calculations were performed for 18 nm NPs with
surface charges ranging from 4 to −4 e/nm2.
Additional file
Additional file 1: Supporting Information. (DOCX 42 kb)
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